Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinblastine efficacy study in standard-risk pediatric ALK-positive ALCL
2022-501454-11-00Phase 3Authorised
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of vinblastine in anaplastic large cell lymphoma (ALCL), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Probability of event-free survival at 3 years. Planned start Feb 2020; status: authorised.
02
Drugs
vinblastine
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2022-501454-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501454-11-00.